



NextVets Magazine

Volume1(Issue1) June – August 2026

Quality control of vaccines

Dr. Himanshu Sharma

*Assistant Commissioner
C.C.S. National Institute of
Animal Health Baghpat-
250609, Uttar Pradesh
Email id:*

Received: July2026

Published: July2026

©All rights are reserved by **Dr. Himanshu Sharma**

Abstract

Quality control (QC) in vaccines is a critical component of vaccine development, production, and distribution that ensures vaccines are safe, effective, potent, pure, and consistent. It involves a series of standardized tests and regulatory procedures conducted throughout the manufacturing process, from raw material selection to final product release. Quality control evaluates key parameters such as identity, sterility, purity, potency, stability, and safety to ensure that each vaccine batch meets established national and international standards. Adherence to Good Manufacturing Practices (GMP), quality assurance systems, and regulatory guidelines established by organizations such as the World Health Organization (WHO) and national regulatory authorities helps maintain the integrity and reliability of vaccines. In addition, proper storage, transportation, and maintenance of the cold chain are essential to preserve vaccine potency until administration. Continuous monitoring, documentation, and post-marketing surveillance further support vaccine quality by identifying potential issues related to safety or effectiveness. Effective quality control not only safeguards animal and public health but also enhances confidence in vaccination programs, contributes to the prevention and control of infectious diseases, and supports sustainable livestock production and global disease control efforts.

Keywords: Quality control (QC), Vaccines, Vaccine quality, Vaccine safety, Vaccine efficacy

Introduction:

Vaccination is a cornerstone of disease prevention in veterinary medicine, playing a crucial role in protecting animal health, ensuring food security, and mitigating zoonotic risks. The development and production of veterinary vaccines involve complex biological processes that require stringent quality control measures to guarantee safety, efficacy, and consistency. In biomedical research and testing, certain methods have remained largely unchanged since their inception, particularly in vaccine potency measurement. Potency testing is a crucial evaluation parameter that involves *in vitro* and *in vivo* tests to determine the vaccine's specific ability to produce the intended immune response. These tests ensure that vaccines elicit a sufficient and reproducible immune response to protect animals against infectious diseases.

Veterinary vaccines, derived from living organisms, differ significantly from chemical pharmaceuticals due to their complex molecular structures and potential batch-to-batch variability. Unlike synthetic drugs, which have precise and consistent chemical compositions, biological products such as vaccines

are subject to variations inherent to biological systems. This variability necessitates strict control measures to ensure product consistency, safety, and efficacy. The production of veterinary vaccines requires advanced biotechnological methods, including cell culture, genetic engineering, and fermentation processes, to create immunogenic and stable products.

Manufacturers bear the legal responsibility for the quality, safety, and efficacy of vaccines produced and marketed, adhering to national and international regulatory guidelines. These regulations, established by organizations such as the World Organisation for Animal Health (WOAH), the European Medicines Agency (EMA), and the United States Department of Agriculture (USDA), set stringent criteria for vaccine approval, batch release, and post-marketing surveillance.

The primary goal of vaccine manufacturers is to ensure quality through rigorous in-process and final product testing. This objective is achieved through Good Manufacturing Practices (GMP) and the continuous improvement of testing methodologies, including the adoption of alternative methods aligned with the principles of the 3Rs

(Replacement, Reduction, and Refinement). The integration of innovative approaches, such as molecular assays, in-vitro immunoassays, and computational modeling, has enhanced vaccine quality assessment, reducing reliance on traditional in-vivo testing while maintaining robust quality assurance standards.

Rules Governing Quality Control:

1. Every regulatory approval holder must establish an independent quality control department with adequate resources and qualified personnel.
2. The head of QC is responsible for:
 - Approval or rejection of materials and products.
 - Evaluation of batch records.
 - Execution of necessary testing and validation.
 - Approval of specifications, test methods, and quality control procedures.
 - Oversight of contract analysts, equipment maintenance, and personnel training.
3. The QC department must establish, validate, and implement all quality control procedures, manage reference samples, monitor product stability, and handle product quality complaints.

4. Finished product assessment involves reviewing production conditions, in-process testing, compliance with specifications, and final product examination.
5. In-process controls should be conducted at appropriate production stages to ensure product quality.
6. Continuous monitoring of production data, such as fermentation parameters, is required for specific processes.

Good Practices for Quality Control in Laboratories:

Laboratory Premises and Equipment:

- Facilities and equipment must comply with QC requirements based on manufacturing scale and nature.
- External laboratories may be used for testing under documented regulatory guidelines.

Documentation:

- The QC department must maintain:
- Specifications and sampling procedures.
- Testing methods, records, and analytical reports.
- Environmental monitoring data, equipment calibration records, and

validation documents.

- Retention of batch records for at least one year after expiry or as per regulatory requirements.
- Records structured for trend evaluation of analytical data.

Sampling Procedures:

- Sampling must follow written procedures detailing the method, equipment, sample quantity, storage, and handling conditions.
- QC personnel must have access to production areas for sampling and investigation.
- Two types of retained samples:
 - **Reference Sample:** Stored for potential future analysis.
 - **Retention Sample:** Fully packaged unit for identification and re-testing.
- Samples must be representative of each batch and stored at recommended conditions.

Testing:

- Analytical methods must be validated and executed per approved protocols.
- Test records must include product details, batch numbers, specifications, testing results, dates, personnel signatures, and approval status.
- In-process control methods must

be documented and approved by QC.

Batch Tests for Immunological Products:

Batch or Serial Release for Distribution:

- Each batch must be tested for purity, potency, and safety before release.
- In regions with regulatory re-testing programs, batches must be submitted for independent governmental testing.
- Unsatisfactory batches must be withheld, and subsequent batches prioritized for re-testing.

Batch or Serial Purity Test:

- Purity testing involves screening for contaminants in master seeds, cell cultures, animal-origin ingredients, and final products.
- Special documentation is required for fetal or calf serum to verify freedom from contaminations as well as specific immunoglobulins.
- Vaccine manufacturers must follow measures to minimize contamination risks.

Batch or Serial Safety Test:

- Many regulatory authorities waive batch safety testing for seed-lot-based vaccines.
- Where required, safety tests are performed in target or laboratory

animals using fewer subjects than during initial licensing tests.

- Local and systemic reactions must align with regulatory approvals and product literature.

Batch or Serial Potency Test:

- Potency tests correlate with host animal efficacy studies.
- Inactivated vaccines may be tested in laboratory animals or using validated in-vitro antigen quantification.
- Live vaccines are tested via bacterial counts or viral titration.
- Recombinant vaccines undergo similar testing to traditional live vaccines.
- Regulatory bodies set specific bacterial or viral content thresholds to ensure vaccine efficacy throughout its shelf life.

Additional Quality Control Tests:

- Depending on the vaccine type, additional tests may include:
 - Moisture content in desiccated vaccines.
 - Residual inactivant levels in killed vaccines.
 - Completeness of inactivation.
 - pH, preservative, and antibiotic levels.
 - Adjuvant stability.
 - Vacuum retention in desiccated products.

- General physical examination of the final product.
- Samples tested for sterility must be representative of the batch.

Regulatory Framework:

Veterinary regulatory protocols are enforced by national and international organizations responsible for overseeing veterinary product development. Regulatory agencies ensure that all veterinary products, including vaccines, meet specific standards before they can be marketed and used.

International Standards:

Organizations such as the WOA and the Codex Alimentarius Commission establish global guidelines for veterinary product registration and safety assessment. These guidelines help harmonize regulatory approaches across different countries, facilitating the approval and trade of veterinary medicines.

National Regulatory Authorities:

Each country has its regulatory body responsible for evaluating and approving veterinary medicines. For example:

- **United States:** The Food and Drug Administration (FDA) oversees veterinary medicinal products through its Center for Veterinary Medicine (CVM).

- **European Union:** The European Medicines Agency (EMA) coordinates the approval of veterinary vaccines and medicines across member states.
- **India:** The Central Drugs Standard Control Organization (CDSCO) regulates veterinary pharmaceuticals.
- **Other Regions:** Various nations have established independent regulatory frameworks to ensure the safe use of veterinary products.

Legislative Framework:

Most regulatory agencies operate under a legal framework that mandates the submission of clinical trial data, adherence to Good Manufacturing Practices (GMP), and post-market surveillance of veterinary pharmaceuticals. The legislative framework also includes:

- **Risk-Benefit Analysis:** Ensuring that the benefits of a veterinary vaccine outweigh potential risks before approval.
- **Data Protection and Intellectual Property:** Protecting proprietary information related to vaccine formulations and clinical trial results.

Vaccine Approval Process:

The approval of veterinary vaccines follows a structured process

to ensure their efficacy and safety before they reach the market. This process includes the following stages:

Preclinical Research:

This phase involves laboratory testing and in-vitro studies to assess vaccine viability, antigen stability, and initial safety profiling. Researchers evaluate immunogenicity and possible side effects before advancing to animal trials.

Clinical Trials:

Conducted in multiple phases, these trials evaluate the vaccine's effectiveness in target animal species and identify any potential adverse reactions.

Phase I: Small-scale studies to assess safety and appropriate dosage.

Phase II: Expanded trials to evaluate immune response and protection levels.

Phase III: Large-scale trials to confirm efficacy and monitor side effects under field conditions.

Regulatory Submission:

Manufacturers must submit a comprehensive dossier to the relevant regulatory authority, including safety data, efficacy studies, and production protocols. The dossier typically includes:

- Pharmacological and Toxicological Data

- Efficacy and Immunogenicity Studies
- Production and Manufacturing Processes
- Environmental Impact Assessments

Evaluation and Licensing:

Regulatory authorities review submitted data, conduct inspections of manufacturing facilities, and assess risk-benefit analysis before granting approval. This stage may involve expert panels reviewing the data to ensure thorough vetting before licensing.

Post-Marketing Surveillance:

Once approved, vaccines undergo continuous monitoring to detect any long-term safety concerns or adverse effects through pharmacovigilance programs. These include:

- Adverse Event Reporting Systems
- Lot Release Testing
- Field Performance Monitoring

Quality Control & Safety Standards:

Ensuring the quality and safety of veterinary vaccines is paramount in regulatory protocols. Quality control measures include:

Good Manufacturing Practices (GMP):

Regulatory agencies mandate compliance with GMP to ensure

consistent production standards and prevent contamination. Key aspects of GMP include:

- Standard Operating Procedures (SOPs)
- Facility and Equipment Standards
- Personnel Training Requirements

Batch Testing and Validation:

Every batch of vaccine produced must undergo rigorous testing for purity, potency, and sterility before release. This ensures:

- Consistency Across Batches
- Sterility and Stability Verification
- Absence of Contaminants

Stability Studies:

Long-term and accelerated stability studies are conducted to determine the shelf life and storage requirements of veterinary vaccines. This includes:

- Temperature Sensitivity Testing
- Impact of Storage Conditions

Adverse Event Monitoring:

Veterinary pharmacovigilance systems track reports of adverse reactions to identify potential risks and implement corrective actions if necessary. Monitoring systems include:

- Surveillance Programs
- Veterinary Practitioner Reports
- Manufacturer Follow-Ups

Implementation & Compliance:

To maintain compliance with veterinary regulatory protocols, manufacturers, distributors, and veterinary professionals must adhere to several key implementation strategies:

Documentation and Record-Keeping:

Accurate and complete records of vaccine production, distribution, and adverse event reports are essential for regulatory audits and inspections. Required documentation includes:

- Batch Production Records
- Shipping and Distribution Logs
- Adverse Event Reports

Inspections and Audits:

Regulatory authorities conduct routine inspections of manufacturing facilities and distribution networks to ensure ongoing compliance. Inspections focus on:

- Production Facility Standards
- Testing and Quality Control Measures
- Adherence to Approved Manufacturing Protocols

Conclusion:

Veterinary regulatory protocols play a crucial role in safeguarding animal and public health by ensuring that veterinary vaccines meet rigorous safety and efficacy

standards. The approval process involves multiple layers of evaluation, including preclinical and clinical trials, regulatory review, and post-market surveillance. Adherence to GMP, quality control measures, and compliance guidelines is essential for maintaining the integrity of the veterinary pharmaceutical industry. As regulations evolve, continuous monitoring and adaptation will be key to sustaining the effectiveness and reliability of veterinary vaccines. In an era of emerging zoonotic diseases and increasing global trade, maintaining robust regulatory oversight is more important than ever.

References:

Please contact the corresponding author.